| dc.contributor.author |
Charafeddine K.M. |
| dc.contributor.author |
Jabbour M.N. |
| dc.contributor.author |
Kadi R.H. |
| dc.contributor.author |
Daher R.T. |
| dc.contributor.editor |
|
| dc.date |
Jun-2012 |
| dc.date.accessioned |
2017-10-05T15:59:34Z |
| dc.date.available |
2017-10-05T15:59:34Z |
| dc.date.issued |
2012 |
| dc.identifier |
10.1309/AJCP4INKZ6LYAQXW |
| dc.identifier.isbn |
|
| dc.identifier.issn |
00029173 |
| dc.identifier.uri |
http://hdl.handle.net/10938/19085 |
| dc.description.abstract |
Serum free light chain (sFLC) assays were shown to improve detection, management, and prognostication in plasma cell disorders. Recently, sFLC assays improved detection of M proteins when combined with standard methods of protein electrophoresis-immunofixation in patients with non-Hodgkin lymphoma-chronic lymphocytic leukemia (NHL-CLL). Incidence of abnormal sFLC ratio (sFLCr) varied from 0percent to 36percent and 29.7percent to 59percent in NHL and CLL, respectively. Increased sFLC levels or abnormal sFLCr predict shorter overall survival in early-stage CLL. Furthermore, abnormal sFLCr correlated with advanced disease stage and poorer outcome. In diffuse large B-cell lymphomas, increased sFLC was demonstrated as an independent, adverse prognostic factor for overall-event-free survival. Moreover, abnormal sFLCr can be a diagnostic tool in central nervous system lymphomas. Finally, the quantitative FLC assay has the potential to become a new, easily measured biomarker for predicting prognosis and enhanced detection in NHL-CLL. It may be used serially at follow-up evaluations to provide clues to relapse. © American Society for Clinical Pathology. |
| dc.format.extent |
|
| dc.format.extent |
Pages: (890-897) |
| dc.language |
English |
| dc.publisher |
CHICAGO |
| dc.relation.ispartof |
Publication Name: American Journal of Clinical Pathology; Publication Year: 2012; Volume: 137; no. 6; Pages: (890-897); |
| dc.relation.ispartofseries |
|
| dc.relation.uri |
|
| dc.source |
Scopus |
| dc.subject.other |
|
| dc.title |
Extended use of serum free light chain as a biomarker in lymphoproliferative disorders: A comprehensive review |
| dc.type |
Article |
| dc.contributor.affiliation |
Charafeddine, K.M., Department of Pathology, Laboratory Medicine, American University of Beirut Medical Center, PO Box 11-0236, Beirut 1107-2020, Lebanon |
| dc.contributor.affiliation |
Jabbour, M.N., Department of Pathology, Laboratory Medicine, American University of Beirut Medical Center, PO Box 11-0236, Beirut 1107-2020, Lebanon |
| dc.contributor.affiliation |
Kadi, R.H., Department of Pathology, Laboratory Medicine, American University of Beirut Medical Center, PO Box 11-0236, Beirut 1107-2020, Lebanon |
| dc.contributor.affiliation |
Daher, R.T., Department of Pathology, Laboratory Medicine, American University of Beirut Medical Center, PO Box 11-0236, Beirut 1107-2020, Lebanon |
| dc.contributor.authorAddress |
Daher, R.T.; Department of Pathology, Laboratory Medicine, American University of Beirut Medical Center, PO Box 11-0236, Beirut 1107-2020, Lebanon; email: rd02@aub.edu.lb |
| dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Pathology and Laboratory Medicine; |
| dc.contributor.authorDepartment |
Pathology and Laboratory Medicine |
| dc.contributor.authorDivision |
|
| dc.contributor.authorEmail |
rd02@aub.edu.lb |
| dc.contributor.faculty |
Faculty of Medicine |
| dc.contributor.authorInitials |
Charafeddine, KM |
| dc.contributor.authorInitials |
Jabbour, MN |
| dc.contributor.authorInitials |
Kadi, RH |
| dc.contributor.authorInitials |
Daher, RT |
| dc.contributor.authorOrcidID |
|
| dc.contributor.authorReprintAddress |
Daher, RT (reprint author), Amer Univ Beirut, Dept Pathol and Lab Med, Med Ctr, POB 11-0236, Beirut 11072020, Lebanon. |
| dc.contributor.authorResearcherID |
|
| dc.contributor.authorUniversity |
American University of Beirut Medical Center |
| dc.description.cited |
ALEXANIAN R, 1975, ARCH INTERN MED, V135, P62, DOI 10.1001-archinte.135.1.62; Asatiani E, 2004, AM J HEMATOL, V77, P144, DOI 10.1002-ajh.20157; Biggar RJ, 2007, J NATL CANCER I, V99, P962, DOI 10.1093-jnci-djm010; BINET JL, 1981, CANCER, V48, P198, DOI 10.1002-1097-0142(19810701)48:1198::AID-CNCR28204801313.0.CO;2-V; Bradwell AR, 2005, CLIN CHEM, V51, P805, DOI 10.1373-clinchem.2005.048017; Bradwell AR, 2001, CLIN CHEM, V47, P673; Cote TR, 1997, INT J CANCER, V73, P645, DOI 10.1002-(SICI)1097-0215(19971127)73:5645::AID-IJC63.0.CO;2-X; Diamantidis MD, 2009, CLIN BIOCHEM, V42, P1202, DOI 10.1016-j.clinbiochem.2009.04.002; Dingli D, 2006, BLOOD, V108, P1979, DOI 10.1182-blood-2006-04-015784; Dispenzieri A, 2009, LEUKEMIA, V23, P215, DOI 10.1038-leu.2008.307; Dispenzieri A, 2006, BLOOD, V107, P3378, DOI 10.1182-blood-2005-07-2922; Dispenzieri A, 2008, BLOOD, V111, P785, DOI 10.1182-blood-2007-08-108357; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056-NEJM200012283432602; Gottenberg JE, 2007, ANN RHEUM DIS, V66, P23, DOI 10.1136-ard.2006.052159; Hamblin TJ, 2002, BLOOD, V99, P1023, DOI 10.1182-blood.V99.3.1023; Hildebrandt B, 2007, BMC CANCER, V7, DOI 10.1186-1471-2407-7-185; Hill PG, 2006, CLIN CHEM, V52, P1743, DOI 10.1373-clinchem.2006.069104; Itzykson R, 2008, HAEMATOL-HEMATOL J, V93, P793, DOI 10.3324-haematol.12107; Katzmann JA, 2005, CLIN CHEM, V51, P878, DOI 10.1373-clinchem.2004.046870; Katzmann JA, 2002, CLIN CHEM, V48, P1437; Krober A, 2002, BLOOD, V100, P1410; Kyle RA, 2007, BRIT J HAEMATOL, V139, P730, DOI 10.1111-j.1365-2141.2007.06873.x; KYLE RA, 1987, MAYO CLIN PROC, V62, P719; Kyrtsonis MC, 2007, BRIT J HAEMATOL, V137, P240, DOI 10.1111-j.1365-2141.2007.06561.x; Landgren O, 2010, J CLIN ONCOL, V28, P773, DOI 10.1200-JCO.2009.25.1322; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056-NEJM198308253090803; Lin Pei, 2005, American Journal of Clinical Pathology, V123, P200, DOI 10.1309-2A0FL1HM5PN2510P; Martin W, 2007, TRANSL RES, V149, P231, DOI 10.1016-j.trsl.2006.11.001; Matrai Z, 2001, BLOOD, V97, P1902, DOI 10.1182-blood.V97.6.1902; Matschke J, 2009, BLOOD, V114, P1237; Maurer MJ, 2011, J CLIN ONCOL, V29, P1620, DOI 10.1200-JCO.2010.29.4413; Maurer MJ, 2011, BLOOD, V118, P2821, DOI 10.1182-blood-2011-04-349134; Moreau A, 2006, BLOOD, V108, p2420a; Nakano T, 2003, J IMMUNOL METHODS, V275, P9, DOI 10.1016-S0022-1759(02)00512-4; Perdigao J, 2008, ANN ONCOL, V19, P204; Pratt G, 2009, BRIT J HAEMATOL, V144, P217, DOI 10.1111-j.1365-2141.2008.07456.x; Rai KR, 2004, HEMATOL ONCOL CLIN N, V18, P795, DOI 10.1016-j.hoc.2004.04.001; Rajkumar SV, 2005, BLOOD, V106, P812, DOI 10.1182-blood-2005-03-1038; Ruchlemer R, 2007, BLOOD, V110, p4697a; Schroers R, 2010, EUR J HAEMATOL, V85, P236, DOI 10.1111-j.1600-0609.2010.01475.x; Seiler T, 2006, SEMIN ONCOL, V33, P186, DOI 10.1053-j.seminoncol.2006.01.017; Tate JR, 2003, CLIN CHEM, V49, P1252, DOI 10.1373-49.8.1252; Tate JR, 2007, CLIN CHIM ACTA, V376, P30, DOI 10.1016-j.cca.2006.07.011; van Rhee F, 2007, BLOOD, V110, P827, DOI 10.1182-blood-2007-01-067728; Vermeersch P, 2008, BRIT J HAEMATOL, V143, P496, DOI 10.1111-j.1365-2141.2008.07369.x; WEISS A, 1992, COLD SPRING HARB SYM, V57, P107; WEISS A, 1994, ADV EXP MED BIOL, V365, P53; Yegin ZA, 2010, EUR J HAEMATOL, V84, P406, DOI 10.1111-j.1600-0609.2010.01412.x |
| dc.description.citedCount |
9 |
| dc.description.citedTotWOSCount |
8 |
| dc.description.citedWOSCount |
8 |
| dc.format.extentCount |
8 |
| dc.identifier.articleNo |
|
| dc.identifier.coden |
AJCPA |
| dc.identifier.pubmedID |
22586047 |
| dc.identifier.scopusID |
84863755369 |
| dc.identifier.url |
|
| dc.publisher.address |
2100 W HARRISON ST, CHICAGO, IL 60612 USA |
| dc.relation.ispartofConference |
|
| dc.relation.ispartofConferenceCode |
|
| dc.relation.ispartofConferenceDate |
|
| dc.relation.ispartofConferenceHosting |
|
| dc.relation.ispartofConferenceLoc |
|
| dc.relation.ispartofConferenceSponsor |
|
| dc.relation.ispartofConferenceTitle |
|
| dc.relation.ispartofFundingAgency |
|
| dc.relation.ispartOfISOAbbr |
Am. J. Clin. Pathol. |
| dc.relation.ispartOfIssue |
6 |
| dc.relation.ispartOfPart |
|
| dc.relation.ispartofPubTitle |
American Journal of Clinical Pathology |
| dc.relation.ispartofPubTitleAbbr |
Am. J. Clin. Pathol. |
| dc.relation.ispartOfSpecialIssue |
|
| dc.relation.ispartOfSuppl |
|
| dc.relation.ispartOfVolume |
137 |
| dc.source.ID |
WOS:000304575700005 |
| dc.type.publication |
Journal |
| dc.subject.otherAuthKeyword |
Chronic lymphocytic leukemia |
| dc.subject.otherAuthKeyword |
Non-Hodgkin lymphoma |
| dc.subject.otherAuthKeyword |
Prognosis |
| dc.subject.otherAuthKeyword |
Serum free light chain |
| dc.subject.otherAuthKeyword |
Serum free light chain ratio |
| dc.subject.otherChemCAS |
Biological Markers |
| dc.subject.otherChemCAS |
Immunoglobulin Light Chains |
| dc.subject.otherIndex |
biological marker |
| dc.subject.otherIndex |
M protein |
| dc.subject.otherIndex |
serum free light chain |
| dc.subject.otherIndex |
unclassified drug |
| dc.subject.otherIndex |
biological marker |
| dc.subject.otherIndex |
immunoglobulin light chain |
| dc.subject.otherIndex |
article |
| dc.subject.otherIndex |
blood level |
| dc.subject.otherIndex |
Burkitt lymphoma |
| dc.subject.otherIndex |
cerebrospinal fluid analysis |
| dc.subject.otherIndex |
chronic lymphatic leukemia |
| dc.subject.otherIndex |
disease severity |
| dc.subject.otherIndex |
event free survival |
| dc.subject.otherIndex |
follow up |
| dc.subject.otherIndex |
human |
| dc.subject.otherIndex |
large cell lymphoma |
| dc.subject.otherIndex |
lymphoproliferative disease |
| dc.subject.otherIndex |
nonhodgkin lymphoma |
| dc.subject.otherIndex |
overall survival |
| dc.subject.otherIndex |
prediction |
| dc.subject.otherIndex |
priority journal |
| dc.subject.otherIndex |
prognosis |
| dc.subject.otherIndex |
protein analysis |
| dc.subject.otherIndex |
protein electrophoresis |
| dc.subject.otherIndex |
quantitative analysis |
| dc.subject.otherIndex |
relapse |
| dc.subject.otherIndex |
B cell lymphoma |
| dc.subject.otherIndex |
blood |
| dc.subject.otherIndex |
cerebrospinal fluid |
| dc.subject.otherIndex |
chronic lymphatic leukemia |
| dc.subject.otherIndex |
disease course |
| dc.subject.otherIndex |
female |
| dc.subject.otherIndex |
immunology |
| dc.subject.otherIndex |
male |
| dc.subject.otherIndex |
paraproteinemia |
| dc.subject.otherIndex |
review |
| dc.subject.otherIndex |
Biological Markers |
| dc.subject.otherIndex |
Disease Progression |
| dc.subject.otherIndex |
Female |
| dc.subject.otherIndex |
Humans |
| dc.subject.otherIndex |
Immunoglobulin Light Chains |
| dc.subject.otherIndex |
Leukemia, Lymphocytic, Chronic, B-Cell |
| dc.subject.otherIndex |
Lymphoma, AIDS-Related |
| dc.subject.otherIndex |
Lymphoproliferative Disorders |
| dc.subject.otherIndex |
Male |
| dc.subject.otherIndex |
Paraproteinemias |
| dc.subject.otherIndex |
Prognosis |
| dc.subject.otherKeywordPlus |
CHRONIC LYMPHOCYTIC-LEUKEMIA |
| dc.subject.otherKeywordPlus |
INDEPENDENT RISK-FACTOR |
| dc.subject.otherKeywordPlus |
MONOCLONAL GAMMOPATHY |
| dc.subject.otherKeywordPlus |
MULTIPLE-MYELOMA |
| dc.subject.otherKeywordPlus |
CD38 EXPRESSION |
| dc.subject.otherKeywordPlus |
UNDETERMINED SIGNIFICANCE |
| dc.subject.otherKeywordPlus |
DIAGNOSTIC PERFORMANCE |
| dc.subject.otherKeywordPlus |
GENOMIC ABERRATIONS |
| dc.subject.otherKeywordPlus |
RATIO |
| dc.subject.otherKeywordPlus |
LYMPHOMA |
| dc.subject.otherWOS |
Pathology |